1947: 
Gebro Pharma is founded by Otto Broschek, Mag. pharm. Grete Broschek and her son Mag. pharm. Herbert Broschek

1947: 
Launch of the manufacturing of local anesthetics (Novanaest®) in Mühlbach am Hochkönig

1949:
Übersiedlung von Gebro Pharma an den heutigen Unternehmensstandort in Fieberbrunn, Tirol

1953:
Entry of Mag. pharm. Helga Broschek, maiden name Luger, who will make a significant contribution to the development of the Gebro Group

1974:
The foundation of the joint venture Zyma-Gebro Arzneimittelvertriebsges.m.b.H., based on the existing concession from 1954

1976:
Foundation of our first wholly subsidiary, today's Gebro Pharma AG, in Switzerland

1982:
To this day, continued cooperation with the Swiss company Gaba, now part of Colgate-Palmolive

1982:
Successful launch of the dental products elmex^® and meridol^® in Austria

1983:
Start of international commercialization of our products via first license partners in Germany

1994:
World's first regulatory approval of dexibuprofen - successful launch of Gebro's proprietary development marketed as Seractil^® in Austria

1996:
Re-branding and expansion of the joint venture Zyma-Gebro Arzneimittelvertriebsges.m.b.H. (today Haleon - Gebro Consumer Health GmbH)

2000: 
The Swiss company Alpinamed AG, a specialized manufacturer of pharmaceutical plant extracts as well as high-quality nutritional supplements and cosmetics, becomes part of the Gebro Group

2000:
Successful launch of Seractil^® (dexibuprofen) in Sweden - first launch of Gebro's proprietary development outside Austria

2000: 
Mag. phil. Pascal Broschek, son of the founding family, becomes a Gebro shareholder

2002:
Founding of our first Spanish company, Laboratorios Gebro Pharma S.A., based in Barcelona

2003:
Successful launch of Seractil^® (dexibuprofen) in South Korea - first launch of Gebro's proprietary development outside Europe

2004:
Successful launch of Metoject^® pre-filled syringes in Spain - to be followed shortly by successful launches in Switzerland and Hungary

2005:
Mr. Mag. phil. Pascal Broschek, son of the founding family, joins the Gebro Executive Board

2008:
The Gebro Group's turnover exceeds 100 million euros for the first time

2009:
Mag. pharm. Herbert Broschek, co-founder and main shareholder of Gebro, passes away at the age of 84

2012: 
Successful launch of Seractil^® (dexibuprofen) in Central America - first launch of Gebro's proprietary development on the American continent

2012:
Founding of Gebro Holding GmbH to give the Gebro Group a structure appropriate to its steady growth

2015: 
Mag. pharm. Helga Broschek, co-founder and shareholder of Gebro Holding GmbH, passes away at the age of 88

2015:
The Gebro Group's turnover exceeds 150 million euros for the first time

2016:
Swiss Gebro Pharma A.G. moves into a new building in Liestal

2018:
Gebro acquires two parenteral antihistamines to ensure the availability of the drugs in Austria, Germany, Switzerland and the Netherlands

2019:
Expansion of Swiss Alpinamed AG with a doubling of production volume

2019:
Acquisition of Diliban^® (tramadol/paracetamol) and manufacturing transfer to
Fieberbrunn - Diliban® becomes Gebro's most successful product up to this time

2020:
Gebro opens one of the most cutting-edge laboratories in Europe

2020:
The Gebro Group's turnover exceeds 200 million euros for the first time

2021:
Successful launch of Duplaxil^® (400mg hydroxychloroquine) in Spain

2022:
The Gebro Group achieves an export turnover for the first time of over 50 million euros beyond its established core markets